Jada Lewis

Jada Lewis,

Professor, Deputy Director McKnight Brain Institute

Department: Department of Neuroscience
Business Phone: (352) 273-9666
Business Email: jada.lewis@ufl.edu

Teaching Profile

Courses Taught
2019-2023
GMS5905 Special Topics in Biomedical Sciences
2019
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2019
GMS6705 Functional Human Neuroanatomy
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2013,2015-2017
GMS6750 Molecular Pathobiology of Neural Disease
2011-2015
GMS6792 Neuroscience Graduate Research Seminar
2014
GMS7794 Neuroscience Seminar

Publications

2022
Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.
Free neuropathology. 3(9) [DOI] 10.17879/freeneuropathology-2022-3766. [PMID] 35494163.
2022
TAPPing into the potential of inducible tau/APP transgenic mice.
Neuropathology and applied neurobiology. 48(3) [DOI] 10.1111/nan.12791. [PMID] 35067965.
2021
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Molecular therapy : the journal of the American Society of Gene Therapy. 29(2):859-872 [DOI] 10.1016/j.ymthe.2020.10.007. [PMID] 33128896.
2021
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.
Acta neuropathologica. 141(3):359-381 [DOI] 10.1007/s00401-021-02264-9. [PMID] 33496840.
2020
Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Acta neuropathologica communications. 8(1) [DOI] 10.1186/s40478-020-00911-y. [PMID] 32252825.
2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Molecular neurobiology. 57(4):1986-2001 [DOI] 10.1007/s12035-019-01859-4. [PMID] 31903524.
2018
Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3.
Acta neuropathologica communications. 6(1) [DOI] 10.1186/s40478-018-0631-0. [PMID] 30563574.
2018
Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.
Acta neuropathologica. 136(6):919-938 [DOI] 10.1007/s00401-018-1895-y. [PMID] 30140941.
2018
Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy.
Scientific reports. 8(1) [DOI] 10.1038/s41598-018-21371-4. [PMID] 29511296.
2018
Designing antibodies against LRRK2-targeted tau epitopes.
PloS one. 13(9) [DOI] 10.1371/journal.pone.0204367. [PMID] 30261006.
2018
Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.
Molecular neurodegeneration. 13(1) [DOI] 10.1186/s13024-018-0253-9. [PMID] 29776378.
2018
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
PLoS biology. 16(12) [DOI] 10.1371/journal.pbio.2006265. [PMID] 30571694.
2018
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Molecular and cellular neurosciences. 92:17-26 [DOI] 10.1016/j.mcn.2018.05.009. [PMID] 29859891.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one. 12(5) [DOI] 10.1371/journal.pone.0173565. [PMID] 28467418.
2016
Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.
Alzheimer's research & therapy. 8 [DOI] 10.1186/s13195-016-0202-1. [PMID] 27593210.
2016
Heterogeneity of Matrin 3 in the developing and aging murine central nervous system.
The Journal of comparative neurology. 524(14):2740-52 [DOI] 10.1002/cne.23986. [PMID] 26878116.
2016
Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Acta neuropathologica. 131(1):27-48 [DOI] 10.1007/s00401-015-1507-z. [PMID] 26576562.
2016
Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype.
Acta neuropathologica communications. 4(1) [DOI] 10.1186/s40478-016-0393-5. [PMID] 27863507.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 29(10):4384-98 [DOI] 10.1096/fj.15-275834. [PMID] 26156074.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica. 130(2):303-5 [DOI] 10.1007/s00401-015-1444-x. [PMID] 25982997.
2015
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Journal of neuroscience research. 93(10):1567-80 [DOI] 10.1002/jnr.23614. [PMID] 26123245.
2015
Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis.
RNA (New York, N.Y.). 21(8):1419-32 [DOI] 10.1261/rna.047647.114. [PMID] 26089325.
2015
Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy.
PloS one. 10(11) [DOI] 10.1371/journal.pone.0142144. [PMID] 26528920.
2014
Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study.
Neurobiology of aging. 35(6):1364-74 [DOI] 10.1016/j.neurobiolaging.2013.12.009. [PMID] 24411290.
2014
Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling.
PloS one. 9(1) [DOI] 10.1371/journal.pone.0086513. [PMID] 24466128.
2014
Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Molecular neurodegeneration. 9 [DOI] 10.1186/1750-1326-9-8. [PMID] 24428919.
2014
ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.
Nature communications. 5 [DOI] 10.1038/ncomms4996. [PMID] 24893131.
2014
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
PloS one. 9(1) [DOI] 10.1371/journal.pone.0087383. [PMID] 24489906.
2014
Tau promotes neurodegeneration through global chromatin relaxation.
Nature neuroscience. 17(3):357-66 [DOI] 10.1038/nn.3639. [PMID] 24464041.
2014
Therapeutic and diagnostic challenges for frontotemporal dementia.
Frontiers in aging neuroscience. 6 [DOI] 10.3389/fnagi.2014.00204. [PMID] 25191265.
2014
Understanding the Role of Progranulin in Alzheimer’s Disease
. 20(10):1099-1100
2014
Understanding the role of progranulin in Alzheimer’s disease.
Nature medicine. 20(10):1099-100 [DOI] 10.1038/nm.3712. [PMID] 25295938.
2013
Anti-tau antibodies: hitting the target.
Neuron. 80(2):254-6 [DOI] 10.1016/j.neuron.2013.10.009. [PMID] 24139027.
2013
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Human molecular genetics. 22(10):2067-82 [DOI] 10.1093/hmg/ddt057. [PMID] 23393156.
2013
Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
Journal of Alzheimer's disease : JAD. 33(1):249-63 [DOI] 10.3233/JAD-2012-121093. [PMID] 22941973.
2013
Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-17. [PMID] 23714769.
2013
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Neuron. 79(6):1094-108 [DOI] 10.1016/j.neuron.2013.07.037. [PMID] 24050400.
2013
In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-9. [PMID] 23379588.
2013
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.
Acta neuropathologica. 126(6):809-27 [DOI] 10.1007/s00401-013-1188-4. [PMID] 24113872.
2013
Lrrtm3 Interacts With App and Bace1 and Has Variants Associating With Late-Onset Alzheimer’s Disease (Load)
PLoS One. 8(6) [DOI] 10.1371/journal.pone.0064164. [PMID] 23750206.
2013
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.
Proceedings of the National Academy of Sciences of the United States of America. 110(51):E4968-77 [DOI] 10.1073/pnas.1315438110. [PMID] 24248382.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica. 126(1):39-50 [DOI] 10.1007/s00401-013-1123-8. [PMID] 23666556.
2013
Thinking laterally about neurodegenerative proteinopathies.
The Journal of clinical investigation. 123(5):1847-55 [DOI] 10.1172/JCI66029. [PMID] 23635781.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.
Brain research. 1524:62-73 [DOI] 10.1016/j.brainres.2013.06.006. [PMID] 23774650.
2012
Achievements and Challenges in Creating Animal Models of Frontotemporal Dementias
Dementia and Geriatric Cognitive Disorders. 33:5-6
2012
Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction.
Acta neuropathologica. 123(6):807-23 [DOI] 10.1007/s00401-012-0979-3. [PMID] 22539017.
2012
Progranulin regulates neuronal outgrowth independent of sortilin.
Molecular neurodegeneration. 7 [DOI] 10.1186/1750-1326-7-33. [PMID] 22781549.
2012
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.
American journal of human genetics. 90(6):1102-7 [DOI] 10.1016/j.ajhg.2012.04.021. [PMID] 22608501.
2011
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.
Molecular neurodegeneration. 6 [DOI] 10.1186/1750-1326-6-73. [PMID] 22029574.
2011
Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy.
Acta neuropathologica. 122(5):551-64 [DOI] 10.1007/s00401-011-0877-0. [PMID] 21968531.
2011
Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.
Brain structure & function. 216(1):31-42 [DOI] 10.1007/s00429-010-0295-4. [PMID] 21152933.
2010
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging.
The American journal of pathology. 177(1):311-24 [DOI] 10.2353/ajpath.2010.090915. [PMID] 20522652.
2010
Amyloid precursor protein and tau transgenic models of Alzheimer’s disease: insights from the past and directions for the future.
Future neurology. 5(3):411-420 [PMID] 20730022.
2010
Sorting out frontotemporal dementia?
Neuron. 68(4):601-3 [DOI] 10.1016/j.neuron.2010.11.014. [PMID] 21092851.
2010
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.
Experimental neurology. 223(2):385-93 [DOI] 10.1016/j.expneurol.2009.07.029. [PMID] 19665462.
2010
Targeting Abeta and tau in Alzheimer’s disease, an early interim report.
Experimental neurology. 223(2):252-66 [DOI] 10.1016/j.expneurol.2009.07.035. [PMID] 19716367.
2010
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(32):10851-9 [DOI] 10.1523/JNEUROSCI.1630-10.2010. [PMID] 20702714.
2009
Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.
The American journal of pathology. 174(1):228-38 [DOI] 10.2353/ajpath.2009.080764. [PMID] 19074615.
2009
Aging is not associated with proteasome impairment in UPS reporter mice.
PloS one. 4(6) [DOI] 10.1371/journal.pone.0005888. [PMID] 19517018.
2008
A novel calcium-binding protein is associated with tau proteins in tauopathy.
Journal of neurochemistry. 106(1):96-106 [DOI] 10.1111/j.1471-4159.2008.05339.x. [PMID] 18346207.
2008
Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.
Journal of Alzheimer's disease : JAD. 15(4):605-14 [PMID] 19096159.
2008
Apparent behavioral benefits of Tau overexpression in P301L Tau transgenic miceIn vivo silencing of alpha-synuclein using naked siRNA
. 15(4):605-614
2008
Biologic models of neurodegenerative disorders.
Handbook of clinical neurology. 89:173-88 [DOI] 10.1016/S0072-9752(07)01216-X. [PMID] 18631742.
2008
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 28(4):862-7 [DOI] 10.1523/JNEUROSCI.3072-08.2008. [PMID] 18216194.
2008
In vivo silencing of alpha-synuclein using naked siRNA.
Molecular neurodegeneration. 3 [DOI] 10.1186/1750-1326-3-19. [PMID] 18976489.
2007
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 27(14):3650-62 [PMID] 17409229.
2007
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice.
The American journal of pathology. 171(6):2012-20 [PMID] 18055549.
2006
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
Proceedings of the National Academy of Sciences of the United States of America. 103(25):9673-8 [PMID] 16769887.
2006
Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice.
Neuroscience letters. 409(2):95-9 [PMID] 17010516.
2005
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(46):10637-47 [PMID] 16291936.
2005
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Proceedings of the National Academy of Sciences of the United States of America. 102(19):6990-5 [PMID] 15867159.
2005
Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology. 34(6):397-410 [PMID] 16902761.
2005
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(5):1226-33 [PMID] 15689560.
2005
Tau suppression in a neurodegenerative mouse model improves memory function
Science. 309(5733):476-481 [DOI] 10.1126/science.1113694. [PMID] 16020737.
2004
Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice.
Neurobiology of disease. 15(3):553-62 [PMID] 15056463.
2004
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Human molecular genetics. 13(7):703-14 [PMID] 14962978.
2004
Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer’s disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Brain research. 1012(1-2):29-41 [PMID] 15158158.
2004
Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Journal of neurochemistry. 90(4):829-38 [PMID] 15287888.
2004
Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau.
The American journal of pathology. 164(1):347-53 [PMID] 14695347.
2004
The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer’s transgenic mice.
Neuroreport. 15(1):73-7 [PMID] 15106834.
2003
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
The American journal of pathology. 163(3):1057-67 [PMID] 12937146.
2003
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.
The American journal of pathology. 162(1):213-8 [PMID] 12507904.
2003
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology. 32(9):1091-105 [PMID] 15044841.
2002
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Journal of neurochemistry. 83(6):1498-508 [PMID] 12472903.
2001
Analysis of tauopathies with transgenic mice
Trends in Molecular Medicine. 7(10):467-470 [DOI] 10.1016/S1471-4914(01)02123-2. [PMID] 11597522.
2001
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Science. 293(5534):1487-1491 [DOI] 10.1126/science.1058189. [PMID] 11520987.
2001
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles
Science. 293(5530):711-714 [DOI] 10.1126/science.1062382. [PMID] 11408621.
2000
Animal Models of tau dysfunction
Neuroscience. 3(5):63-72
2000
Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions.
Brain research. 853(1):5-14 [PMID] 10627302.
2000
Neurofibrillary tangles, amyotrophy, and progressive motor impairment in Tau mutant (P301L) transgenic mice
Nature Genetics. 25:402-405
2000
The molecular genetics of the tauopathies
Experimental Gerontology. 35(4):461-471 [DOI] 10.1016/S0531-5565(00)00114-5. [PMID] 10959034.
1999
5′ Splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10
Journal of Biological Chemistry. 274(21):15134-15143 [DOI] 10.1074/jbc.274.21.15134. [PMID] 10329720.
1999
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
FEBS Letters. 447(2-3):195-199 [DOI] 10.1016/S0014-5793(99)00294-X. [PMID] 10214944.
1998
A common human beta globin splicing mutation modeled in mice
Blood. 91(6):2152-2156 [PMID] 9490703.
1998
Rapid genotyping of mice with hemoglobinopathies and globin transgenes
Biochemical Genetics. 36(1-2):65-77 [DOI] 10.1023/A:1018752219810. [PMID] 9562907.
1996
Gene Modification via plug and socket gene targeting
The Journal of clinical investigation. 97(1):3-5 [DOI] 10.1172/JCI118403. [PMID] 8550847.
1995
A mouse model for beta 0-thalassemia
Proceedings of the National Academy of Sciences. 92(25):11608-11612 [DOI] 10.1073/pnas.92.25.11608. [PMID] 8524813.
1994
Deletion and replacement of the mouse adult beta-globin genes by a “€œplug and socket”€ repeated targeting strategy
Molecular And Cellular Biology. 14(10):6936-6943 [DOI] 10.1128/MCB.14.10.6936. [PMID] 7935410.

Grants

Apr 2022 ACTIVE
Characterization of new CamK2-tau strains of mice to model dementia
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2022 ACTIVE
Contributions of tau-mediated translational dysregulation to pathogenesis and progression of fronto-temporal dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2021 ACTIVE
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2021 ACTIVE
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
May 2021 ACTIVE
Effects of cannabis on Alzheimers disease-related pathology and cognitive decline
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2019 – Aug 2021
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2019 ACTIVE
Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2019 ACTIVE
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Mar 2019 – Feb 2021
The Two Faces of Hypoxia in Alzheimer's Disease
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2018 ACTIVE
Clinical and Translational Pre-doctoral training in Alzheimers Disease and Related Dementias
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jun 2018 ACTIVE
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – May 2018
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017 – Jun 2020
Uncovering targets that block pathological interactions between Abeta and tau
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Mar 2017 ACTIVE
Towards understanding the role of immune regulation of Apolipoprotein E function in Alzheimers disease proteostasis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Feb 2017 – Sep 2019
Large-scale identification of genes that suppress concurrent Abeta42 and tau pathology in vivo
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Dec 2016 – Nov 2019
Is there a form of benign brain amyloidosis in aging?
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2016 – Sep 2019
New mouse models to dissect out the function of the ALS-associated protein Matrin 3
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Aug 2015 – May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Co-Project Director/Principal Investigator
Funding: NATL INST OF HLTH NIA
Jul 2015 – Jun 2018
Towards a knockdown therapy for tauopathy
Role: Principal Investigator
Funding: BRIGHTFOCUS FOU
Apr 2015 – Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jul 2014 – Jun 2017
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Apr 2014 – Mar 2016
Einstein Aging Study Neuropathology Core
Role: Principal Investigator
Funding: MAYO CLINIC via NATL INST OF HLTH
Jul 2013 – Jun 2018
Biological and Pathological Interactions between Tau and LRRK2
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2010 ACTIVE
Animal Models in neurodegenerative Disease
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO

Contact Details

Phones:
Business:
(352) 273-9666
Emails:
Business:
jada.lewis@ufl.edu
Addresses:
Business Mailing:
PO Box 100244
GAINESVILLE FL 32610